Abstracts tagged "depression"

Abstract Number: 1598 • ACR Convergence 2020
Efficacy of Universal Depression Screening in a Rheumatology Clinic
Osman Bhatty¹ and Michael Lucke¹, ¹Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Depression has long been viewed as a comorbid condition in rheumatic diseases. Population studies have confirmed an increased incidence in patients with rheumatoid arthritis,…
Abstract Number: 0194 • ACR Convergence 2020
Depression Symptoms but Not Clinically Diagnosed Depression Predict Mortality in Rheumatoid Arthritis
Jose Felix Restrepo¹, Inmaculada Del Rincon¹ and Agustin Escalante¹, ¹University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX
Background/Purpose: Depression and depressive symptoms are common but under-recognized in rheumatoid arthritis (RA). Few studies have examined depression symptoms in RA patients compared to clinically…
Abstract Number: 1733 • ACR Convergence 2020
Patients with Rheumatoid Arthritis and Comorbid Depression Have High Levels of RAPID3 (Routine Assessment of Patient Index Data) and FAST3 (Fibromyalgia Assessment Screening Index) on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Rosa Morlà¹, Tengfei Li², Jose Inciarte-Mundo³, Isabel Castrejon Fernandez⁴, Jose Gómez-Puerta⁵, Raimon Sanmartí⁵ and Theodore Pincus⁶, ¹Hospital Universitari Clínic de Barcelona, Barcelona, Spain, ²Georgetown University, Washigton, ³Hospital Universitari Clínic de Barcelona, Barcelona, ⁴Hospital General Universitario Gregorio Marañón, Chicago, IL, ⁵Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁶Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher comorbid depression and/or fibromyalgia (FM) than the general population. A multidimensional health-assessment questionnaire (MDHAQ) includes two queries…
Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Laure Gossec¹, Jessica Walsh², Kaleb Michaud³, Elizabeth Holdsworth⁴, Steven Peterson⁵, Sophie Meakin⁴, Nicola Booth⁴, Soumya Chakravarty⁶, James Piercy⁴ and Alexis Ogdie⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…
Abstract Number: 1737 • ACR Convergence 2020
What Influences Fatigue Improvement in Rheumatoid Arthritis? A Prospective Cohort Study
Samar Aboulenain¹, Elie Donath¹ and Ozlem Pala², ¹University of Miami Miller School, West Palm Beach, FL, ²University of Miami Miller School, Fort Lauderdale, FL
Background/Purpose: Fatigue is a common and debilitating complication in patients with rheumatoid arthritis (RA). Its mechanism is not fully elucidated, and when persistent is often…
Abstract Number: 0434 • ACR Convergence 2020
Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease
Patricia Katz¹, Sofia Pedro², Kristin Wipfler³, Teresa Simon⁴, Yomei Shaw⁵, Adam Cornish⁶ and Kaleb Michaud⁷, ¹University of California, San Francisco, Novato, CA, ²FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, ⁵Forward, The National Databank for Rheumatic Diseases, East Lansing, MI, ⁶FORWARD, 68134, NE, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Symptoms of both depression and anxiety are often elevated among individuals with rheumatic conditions, and stress levels may play a role in each. Depression,…
Abstract Number: 1804 • ACR Convergence 2020
Impact of the Kynurenine/Tryptophan Pathway on Cognitive Dysfunction and Depression in Systemic Lupus Erythematosus
Erik Anderson¹, Joanna Fishbein², Joseph Hong², Julien Roeser³, Richard Furie⁴, Cynthia Aranow², Bruce Volpe², Betty Diamond⁵ and Meggan Mackay⁶, ¹Feinstein Institutes for Medical Research, New York, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Charles River Laboratories, South San Francisco, CA, ⁴Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁵Northwell Health, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Tryptophan (TRP) is metabolized to kynurenine (KYN), quinolonic acid [QA, a N-methyl D-aspartate receptor (NMDAR) agonist] and kynurenic acid (KA, an NMDAR antagonist). KYN/TRP…
Abstract Number: 006 • 2020 Pediatric Rheumatology Symposium
Increasing Rates of Standardized Depression Screening in Youth with Systemic Lupus Erythematosus in a Pediatric Rheumatology Clinic
Victoria Newsome ¹, Jodi Dingle ², Manda Mitchell ³, Thomas Brent Graham ⁴ and Alaina Davis⁵, ¹Nashville, ²Vanderbilt University Medical Center, Nashville, Tennessee, ³Nashville, Tennessee, ⁴Vanderbilt University Medical Center, Nashville, ⁵Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee
Background/Purpose: Depression is common among youth with SLE. Early identification and treatment of depression has the potential to improve health outcomes for youth with SLE.…
Abstract Number: 049 • 2020 Pediatric Rheumatology Symposium
Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures
Danielle Fair¹, Judyann Olson ², Jan Lemke ³, Stella Protopapas ⁴, Ke Yan ⁵ and Jian Zhang ⁶, ¹Medical College of Wisconsin & Affiliated Hospitals: Children's Wisconsin, Wauwatosa, Wisconsin, ²Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ³Children's Wisconsin, Milwaukee, Wisconsin, ⁴Riley Children’s Hospital at Indiana University, Indianapolis, Indiana, ⁵Medical College of Wisconsin, Milwaukee, Wisconsin, ⁶Medical College of Wisconsin, 53226, Wisconsin
Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population. Children with JIA experience…
Abstract Number: 134 • 2020 Pediatric Rheumatology Symposium
Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
Michelle Quilter¹, Katherine Cost ², Reva Schachter ³, Julie Couture ⁴, Ashley Danguecan ⁵, Lawrence Ng ⁶, Daniela Dominguez ⁶, Linda Hiraki ⁷, Deborah Levy ⁸, Earl D. Silverman ⁹, Kate Neufeld ¹⁰, Andrea Knight ¹¹ and Daphne Korczak ², ¹Dept. of Psychiatry, Hospital for Sick Children, Dept. of Psychiatry, University of Toronto, Toronto, Ontario, Canada, ²Dept. of Psychiatry, Hospital for Sick Children, Dept. of Psychiatry, University of Toronto, Toronto, Canada, ³Dept. of Psychiatry, Hospital for Sick Children,, Toronto, Canada, ⁴Division of Pediatric Rheumatology-Immunology, CHU Sainte-Justine, Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada, ⁵Hospital for Sick Children, Toronto, Canada, ⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Canada, ⁹Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ¹⁰University of Toronto, The Hospital for Sick Children, Toronto, Canada, ¹¹SickKids Research Institute, Toronto, Canada
Background/Purpose: Screening for co-morbid psychiatric disorder is of high clinical importance in childhood-onset systemic lupus erythematosus (cSLE). However, there are no validated screening measures for…
Abstract Number: 1341 • 2019 ACR/ARP Annual Meeting
Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Shmuel Tiosano ¹, Yarden Yavne ¹, Abdulla Watad ², Pnina Langevitz ³, Merav Lidar ⁴, Joy Feld ⁵, Moshe Tishler ⁶, Suhail Aamar ⁷, Ori Elkayam ⁸, Alexandra Balbir-Gurman ⁹, Yair Molad ¹⁰, Sharon Ehrlich ¹¹, Daniela Amital ¹² and Howard AMITAL¹, ¹Department of Medicine B, Ramat-Gan, Israel, ²Department of Medicine “B”, Zabludowicz Center for Autoimmune Diseases Sheba Medical Center, Ramat-Gan, Israel, ³Rhematology Unit, Ramat-Gan, Israel, ⁴Rheumatology Unit Sheba Medical Center, Ramat Gan, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶5Internal Department B, Assaf Harofeh Medical Center, Zrifin, Israel, Zrifin, Israel, ⁷Rheumatology Unit, Hadassah Mount Scopus Medical Center, Jeursalem, Israel, Jerusalem, Israel, ⁸Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁹Rambam Medical Center, Haifa, Israel, ¹⁰Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, HaMerkaz, Israel, ¹¹Roche Pharmaceuticals (Israel) Ltd., Hod HaSharon, Israel., Hod-Hashaon, Israel, ¹²Ness Ziona Beer-Yaacov Mental Health Center,, Beer-Yaakov, Israel
Background/Purpose: Mood disorders, such as anxiety and depression are extremely prevalent amongst patients with rheumatoid arthritis (RA). In this study we sought to assess the…
Abstract Number: 1414 • 2019 ACR/ARP Annual Meeting
Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab
Frank Behrens¹, Werner A Biewer ², Gerd Burmester ³, Martin Feuchtenberger ⁴, Michael W. Hofmann ⁵, Peter Kästner ⁶, Herbert Kellner ⁷, Ramona König ⁸, Anke Liebhaber ⁹, Christina Luig ¹⁰, Regina Max ¹¹, Patrizia Sternad ¹², Hans-Peter Tony ¹³ and Christopher Amberger ¹⁴, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Rheumatologische Schwerpunktpraxis Saarbrücken, Saarbrücken, Germany, ³Charité—University Medicine Berlin, Berlin, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Chugai Pharma Europe Ltd., Frankfurt/Main, Germany, ⁶MVZ Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁷Praxis Prof. Herbert Kellner, Munich, Germany, ⁸Justus-Liebig-Universität Giessen and Kerckhoff-Klinik-Forschungs-GmbH, Giessen, Germany, ⁹Internistisch-Rheumatologische Arztpraxis, Halle, Halle, Germany, ¹⁰Roche Pharma AG, Rheumatologie, Grenzach-Wyhlen, Germany, ¹¹Universitätsklinikum Heidelberg, Heidelberg, Germany, ¹²Gemeinschaftspraxis, Planegg, Planegg, Germany, ¹³Department of Rheumatology/Clinical Immunology, University Hospital, Wuerzburg, Germany, Würzburg, Germany, ¹⁴Rheumatologische Gemeinschaftspraxis Dr. Pick/Dr. Amberger, Bad Neuenahr, Germany
Background/Purpose: In rheumatoid arthritis (RA), the proinflammatory cytokine IL-6 is associated with mental disorders such as depression and anxiety.1 Furthermore, depression and anxiety are comorbidities…
Abstract Number: 1444 • 2019 ACR/ARP Annual Meeting
Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
Gustavo Citera¹, Rakesh Jain ², Fedra Irazoque ³, Renato Guzman ⁴, Hugo Madariaga ⁵, David Gruben ⁶, Lisy Wang ⁶, Lori Stockert ⁷, Ming-Ann Hsu ⁸, Karina Santana ⁹, Abbas Ebrahim ¹⁰ and Dario Ponce de Leon ¹¹, ¹Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²Texas Tech University School of Medicine, Lubbock, TX, ³Hospital Angeles Mocel, San Miguel, Mexico, ⁴Fundación Universitaria Juan N. Corpas e IDEARG, Bogota, Colombia, ⁵Clínica del Sur, Arequipa, Peru, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, ⁹Pfizer Inc, Mexico City, Mexico, ¹⁰Pfizer Inc, Collegeville, ¹¹Pfizer Inc, Lima, Peru
Background/Purpose: Depression and anxiety are common in patients (pts) with RA1 and can lead to reduced quality of life, functional capacity, and RA treatment response.2-4…
Abstract Number: 1490 • 2019 ACR/ARP Annual Meeting
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Lihi Eder¹, Alexis Ogdie ² and Yujie Zhong ³, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³School of Statistics and Management, Shanghai University of Finance and Economics, Cambridge, China (People's Republic)
Background/Purpose: The prevalence of depression is increased in patients with psoriatic arthritis (PsA). Little is known about the impact of effective control of inflammation on…
Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Jeffrey Sparks¹, Susan Malspeis ¹, Jill Hahn ², Andrea Roberts ², Laura Kubzansky ² and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…

« Previous Page
1
…
6
7
8
9
10
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].